These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25037257)

  • 1. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
    Choi JN
    Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
    Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
    Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor.
    Fawaz B; Dickson L; Menter A
    J Dermatolog Treat; 2016 Oct; 27(5):418-21. PubMed ID: 27080364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
    Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
    Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
    Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
    Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
    Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
    Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J; Mateus C; Wechsler J; Spatz A; Robert C
    Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
    Reyes-Habito CM; Roh EK
    J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.